VASP activation via the Gα13/RhoA/PKA pathway mediates cucurbitacin-B-induced actin aggregation and cofilin-actin rod formation

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhang, Yan Ting ^a   Xu, Li Hui ^a   Lu, Qun ^b   Liu, Kun Peng ^a   Liu, Pei Yan ^c   Ji, Fang ^d   Liu, Xiao Ming ^e   Ouyang, Dong Yun ^a   He, Xian Hui ^a  

^a JINAN UNIVERSITY   (China)

^b EAST CAROLINA UNIVERSITY   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^d Guangdong Academy of Sciences   (China)

^e South China Primate Research and Development Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; COFILIN; CUCURBITACIN; CUCURBITACIN B; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; N (2 PHENYLCYCLOPENTYL)AZACYCLOTRIDECAN 2 IMINE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN GALPHA13; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ACTIN DEPOLYMERIZING FACTOR; CELL ADHESION MOLECULE; PHOSPHOPROTEIN; PROTEIN AGGREGATE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, MOUSE; TRITERPENE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ACTIN FILAMENT; ANIMAL CELL; ARTICLE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY;

ACTIN CYTOSKELETON; ACTIN DEPOLYMERIZING FACTORS; ANIMALS; CARCINOGENESIS; CELL ADHESION MOLECULES; CELL CYCLE; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PROTEIN AGGREGATES; RHO GTP-BINDING PROTEINS; TRITERPENES;

EID: 84898636006     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093547     Document Type: Article

References (43)

1. Konoshima T, Takasaki M, Kozuka M, Nagao T, Okabe H, et al. (1995) Inhibitory effects of cucurbitane triterpenoids on Epstein-Barr virus activation and two-stage carcinogenesis of skin tumor. II. Biol Pharm Bull 18: 284-287.
2. Lui VW, Yau DM, Wong EY, Ng YK, Lau CP, et al. (2009) Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 30: 2085-2094.
3. Promkan M, Dakeng S, Chakrabarty S, Bogler O, Patmasiriwat P (2013) The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells. PLoS One 8: e55732.
4. Chen X, Bao J, Guo J, Ding Q, Lu J, et al. (2012) Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs 23: 777-787.
5. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, et al. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279. (Pubitemid 36348705)
6. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, et al. (2005) Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24: 3236-3245. (Pubitemid 40695105)
7. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, et al. (2009) Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 69: 5876-5884.
8. Chan KT, Li K, Liu SL, Chu KH, Toh M, et al. (2010) Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 289: 46-52.
9. Yin D, Wakimoto N, Xing H, Lu D, Huynh T, et al. (2008) Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 123: 1364-1375.
10. Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE, Bergman M (2007) Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 73: 56-67. (Pubitemid 44853933)
11. Boykin C, Zhang G, Chen YH, Zhang RW, Fan XE, et al. (2011) Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation. Br J Cancer 104: 781-789.
12. Zhang YT, Ouyang DY, Xu LH, Ji YH, Zha QB, et al. (2011) Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen speciesdependent actin aggregation in melanoma cells. Acta Biochim Biophys Sin 43: 556-567.
13. Knecht DA, LaFleur RA, Kahsai AW, Argueta CE, Beshir AB, et al. (2010) Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. PLoS One 5: e14039.
14. Zhu JS, Ouyang DY, Shi ZJ, Xu LH, Zhang YT, et al. (2012) Cucurbitacin B induces cell cycle arrest, apoptosis and autophagy associated with G actin reduction and persistent activation of cofilin in Jurkat cells. Pharmacology 89: 348-346.
15. Wakimoto N, Yin D, O'Kelly J, Haritunians T, Karlan B, et al. (2008) Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 99: 1793-1797.
16. Haritunians T, Gueller S, Zhang L, Badr R, Yin D, et al. (2008) Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 32: 1366-1373.
17. Zhang YT, Ouyang DY, Xu LH, Zha QB, He XH (2013) Formation of cofilinactin rods following cucurbitacin-B-induced actin aggregation depends on slingshot homolog 1-mediated cofilin hyperactivation. J Cell Biochem 10: 2415-2429.
18. Dinan L, Whiting P, Girault JP, Lafont R, Dhadialla TS, et al. (1997) Cucurbitacins are insect steroid hormone antagonists acting at the ecdysteroid receptor. Biochem J 327 (Pt 3): 643-650. (Pubitemid 27487667)
19. Duncan KL, Duncan MD, Alley MC, Sausville EA (1996) Cucurbitacin Einduced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol 52: 1553-1560. (Pubitemid 26375461)
20. Momma K, Masuzawa Y, Nakai N, Chujo M, Murakami A, et al. (2008) Direct interaction of Cucurbitacin E isolated from Alsomitra macrocarpa to actin filament. Cytotechnology 56: 33-39.
21. Nakashima S, Matsuda H, Kurume A, Oda Y, Nakamura S, et al. (2010) Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells. Bioorg Med Chem Lett 20: 2994-2997.
22. Ren S, Ouyang DY, Saltis M, Xu LH, Zha QB, et al. (2012) Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation. Cancer Chemother Pharmacol 70: 415-424.
23. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB (2003) Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annual review of cell and developmental biology 19: 541-564. (Pubitemid 37487360)
24. Trichet L, Sykes C, Plastino J (2008) Relaxing the actin cytoskeleton for adhesion and movement with Ena/VASP. J Cell Biol 181: 19-25. (Pubitemid 351519760)
25. Walders-Harbeck B, Khaitlina SY, Hinssen H, Jockusch BM, Illenberger S (2002) The vasodilator-stimulated phosphoprotein promotes actin polymerisation through direct binding to monomeric actin. FEBS Lett 529: 275-280.
26. Bear JE, Gertler FB (2009) Ena/VASP: towards resolving a pointed controversy at the barbed end. J Cell Sci 122: 1947-1953.
27. Thomson DM, Ascione MP, Grange J, Nelson C, Hansen MD (2011) Phosphorylation of VASP by AMPK alters actin binding and occurs at a novel site. Biochem Biophys Res Commun 414: 215-219.
28. Kataoka A, Koga Y, Uesugi A, Tozaki-Saitoh H, Tsuda M, et al. (2011) Involvement of vasodilator-stimulated phosphoprotein in UDP-induced microglial actin aggregation via PKC- and Rho-dependent pathways. Purinergic Signal 7: 403-411.
29. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, et al. (2004) A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J Neurosci 24: 4070-4081. (Pubitemid 38544233)
30. Benz PM, Blume C, Seifert S, Wilhelm S, Waschke J, et al. (2009) Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci 122: 3954-3965.
31. Benz PM, Blume C, Moebius J, Oschatz C, Schuh K, et al. (2008) Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alphaII-spectrin-VASP complexes. J Cell Biol 180: 205-219.
32. Profirovic J, Gorovoy M, Niu J, Pavlovic S, Voyno-Yasenetskaya T (2005) A novel mechanism of G protein-dependent phosphorylation of vasodilatorstimulated phosphoprotein. J Biol Chem 280: 32866-32876. (Pubitemid 41368335)
33. Kwiatkowski AV, Gertler FB, Loureiro JJ (2003) Function and regulation of Ena/VASP proteins. Trends Cell Biol 13: 386-392. (Pubitemid 36776716)
34. Harbeck B, Huttelmaier S, Schluter K, Jockusch BM, Illenberger S (2000) Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 275: 30817-30825.
35. Chern Y (2000) Regulation of adenylyl cyclase in the central nervous system. Cell Signal 12: 195-204. (Pubitemid 30214223)
36. Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, et al. (1998) p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 280: 2109-2111. (Pubitemid 28366202)
37. Juneja J, Casey PJ (2009) Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol 158: 32-40.
38. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420: 629-635. (Pubitemid 36764489)
39. Lopez-Haber C, Kazanietz MG (2013) Cucurbitacin I inhibits Rac1 activation in breast cancer Cells by a reactive oxygen species-mediated mechanism and independently of Janus tyrosine kinase 2 and P-Rex1. Mol Pharmacol 83: 1141-1154.
40. Lang AE, Schmidt G, Sheets JJ, Aktories K (2011) Targeting of the actin cytoskeleton by insecticidal toxins from Photorhabdus luminescens. Naunyn Schmiedebergs Arch Pharmacol 383: 227-235.
41. Mannock DA, Lewis RN, McMullen TP, McElhaney RN (2010) The effect of variations in phospholipid and sterol structure on the nature of lipid-sterol interactions in lipid bilayer model membranes. Chem Phys Lipids 163: 403-448.
42. Paila YD, Chattopadhyay A (2009) The function of G-protein coupled receptors and membrane cholesterol: specific or general interaction? Glycoconj J 26: 711-720.
43. Oates J, Watts A (2011) Uncovering the intimate relationship between lipids, cholesterol and GPCR activation. Curr Opin Struct Biol 21: 802-807.